Therapeutic drug monitoring is becoming increasingly important in clinical decision-making in children with inflammatory bowel disease (IBD). However, enzyme-linked immunosorbent assay (ELISA) assays do not allow results to be provided in real-time. We sought to compare 2 point-of-care (POC) devices for quantification of serum infliximab concentration with 2 validated ELISA assays in children with IBD.

Determination of Serum Infliximab Concentration by Point-of-care Devices in Children with Inflammatory Bowel Disease

Curci D.;Bramuzzo M.;Favretto D.;FABRIS, MARTINO;VASCOTTO, FULVIA;Naviglio S.;Stocco G.;Decorti G.
2019-01-01

Abstract

Therapeutic drug monitoring is becoming increasingly important in clinical decision-making in children with inflammatory bowel disease (IBD). However, enzyme-linked immunosorbent assay (ELISA) assays do not allow results to be provided in real-time. We sought to compare 2 point-of-care (POC) devices for quantification of serum infliximab concentration with 2 validated ELISA assays in children with IBD.
Pubblicato
https://journals.lww.com/jpgn/fulltext/2019/10000/Determination_of_Serum_Infliximab_Concentration_by.17.aspx
File in questo prodotto:
File Dimensione Formato  
curci.pdf

Accesso chiuso

Tipologia: Documento in Versione Editoriale
Licenza: Copyright Editore
Dimensione 220.95 kB
Formato Adobe PDF
220.95 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11368/2951648
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 7
social impact